{
    "name": "pirtobrutinib",
    "comment": "Rx",
    "other_names": [
        "Jaypirca"
    ],
    "classes": [
        "Antineoplastics",
        "Tyrosine Kinase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/jaypirca-pirtobrutinib-4000314",
    "pregnancy": {
        "common": [
            "Based on findings from animal studies, fetal harm may cause when administered to pregnant females",
            "No data are available on use in pregnant females to evaluate for a drug-associated risk",
            "Verify pregnancy status in females of reproductive potential before initiating"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 1 week after last dose"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Doses â‰¥375 mg/kg BID caused decreased fetal body weights and increased incidence of malformations and variations in urinary tract (including absent or abnormal ureters and kidneys), reproductive tract (mispositioned ovaries and misshapen uterus), and bone (misshapen sternebrae)",
                    "At 500 mg/kg BID, total resorption observed",
                    "At 375 mg/kg BID in rats, maternal systemic exposures (AUC) were ~3 times the human exposure at 200 mg qDay",
                    "Advise pregnant females of potential risk to a fetus"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on drug presence in human milk or the effects on breastfed children or milk production",
            "Advise females not to breastfeed during treatment and for 1 week after last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "For all adverse reactions, based on severity, reduce dose, temporarily withhold, or permanently discontinue",
                "Grade 3 or 4 cytopenias, including neutropenia, anemia, and thrombocytopenia reported; monitor complete blood cell counts regularly during treatment ",
                "Atrial fibrillation and atrial flutter occurred; monitor for signs and symptoms of arrhythmias (eg, palpitations, dizziness, syncope, dyspnea) and manage appropriately",
                "Second primary malignancies, including non-skin carcinomas, developed; advise patients to use sun protection and monitor for development of second primary malignancies",
                "Based on findings in animals, fetal harm may occur when administered to pregnant females"
            ],
            "specific": [
                {
                    "type": "Infections",
                    "description": [
                        "Serious and fatal infections (eg, bacterial, viral, or fungal) and opportunistic infection reported",
                        "Consider antimicrobial prophylaxis and vaccinations in patients who are at increased risk for infections",
                        "Monitor for signs and symptoms of infection, evaluate promptly, and treat appropriately"
                    ]
                },
                {
                    "type": "Hemorrhage",
                    "description": [
                        "Serious and fatal hemorrhage occurred",
                        "Major hemorrhage occurred at a higher incidence in patients taking pirtobrutinib without antithrombotic agents than in those taking pirtobrutinib with antithrombotic agents (1.7% vs 0.7%)",
                        "Consider the risks and benefits of antithrombotic agents when coadministered with pirtobrutinib",
                        "Monitor for signs of bleeding",
                        "Consider the benefit-risk of withholding pirtobrutinib for 3-7 days pre- and post-surgery depending upon type of surgery and risk of bleeding"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "CYP3A4 substrate",
                        "P-gp inhibitor",
                        "Moderate CYP2C8 and BCRP inhibitor",
                        "Weak CYP2C19 and CYP3A inhibitor",
                        "Strong CYP3A inhibitors",
                        "Avoid coadministration; if unavoidable, reduce pirtobrutinib dose ",
                        "Strong CYP3A inhibitors increase pirtobrutinib systemic exposure and risk for adverse reactions",
                        "Strong or moderate CYP3A inducers",
                        "Avoid coadministration",
                        "If use of moderate CYP3A inducers is unavoidable, increase pirtobrutinib dose",
                        "Strong or moderate CYP3A inducers decrease pirtobrutinib systemic exposure and may reduce pirtobrutinib efficacy ",
                        "Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP substrates",
                        "Pirtobrutinib may increase plasma concentrations of sensitive P-gp, CYP2C8, BCRP, which may increase the risk of adverse reactions related to these substrates",
                        "Refer to prescribing information for sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP substrates for dosing recommendations "
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Hemoglobin decreased",
            "percent": "42"
        },
        {
            "name": "Platelet count decreased",
            "percent": "39"
        },
        {
            "name": "Neutrophil count decreased",
            "percent": "36"
        },
        {
            "name": "Lymphocyte count decreased",
            "percent": "32"
        },
        {
            "name": "Creatinine increased",
            "percent": "30"
        },
        {
            "name": "Fatigue",
            "percent": "29"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "27"
        },
        {
            "name": "Edema",
            "percent": "19"
        },
        {
            "name": "Diarrhea",
            "percent": "19"
        },
        {
            "name": "Calcium decreased",
            "percent": "19"
        },
        {
            "name": "Dyspnea",
            "percent": "17"
        },
        {
            "name": "AST increased",
            "percent": "17"
        },
        {
            "name": "Cough",
            "percent": "16"
        },
        {
            "name": "Bruising",
            "percent": "16"
        },
        {
            "name": "Pneumonia",
            "percent": "16"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "14"
        },
        {
            "name": "Rash",
            "percent": "14"
        },
        {
            "name": "Fever",
            "percent": "13"
        },
        {
            "name": "Constipation",
            "percent": "13"
        },
        {
            "name": "Potassium decreased",
            "percent": "13"
        },
        {
            "name": "Sodium decreased",
            "percent": "13"
        },
        {
            "name": "Lipase increased",
            "percent": "12"
        },
        {
            "name": "Arthritis or arthralgia",
            "percent": "12"
        },
        {
            "name": "Abdominal pain",
            "percent": "11"
        },
        {
            "name": "Nausea",
            "percent": "11"
        },
        {
            "name": "Hemorrhage",
            "percent": "11"
        },
        {
            "name": "Alkaline phosphatase increased",
            "percent": "11"
        },
        {
            "name": "ALT increased",
            "percent": "11"
        },
        {
            "name": "Potassium increased",
            "percent": "11"
        },
        {
            "name": "Neutrophil count decreased",
            "percent": "16"
        },
        {
            "name": "Lymphocyte count decreased",
            "percent": "15"
        },
        {
            "name": "Pneumonia",
            "percent": "14"
        },
        {
            "name": "Platelet count decreased",
            "percent": "14"
        },
        {
            "name": "Upper respiratory tract infections",
            "percent": "10"
        },
        {
            "name": "Dizziness",
            "percent": "10"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "9"
        },
        {
            "name": "Lipase increased",
            "percent": "4.4"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "3.9"
        },
        {
            "name": "Hemorrhage",
            "percent": "3.1"
        },
        {
            "name": "Dyspnea",
            "percent": "2.3"
        },
        {
            "name": "Fatigue",
            "percent": "1.6"
        },
        {
            "name": "ALT or AST increased",
            "percent": "1.6"
        },
        {
            "name": "Creatinine increased",
            "percent": "1.6"
        },
        {
            "name": "Calcium decreased",
            "percent": "1.6"
        },
        {
            "name": "Potassium decreased",
            "percent": "1.6"
        },
        {
            "name": "Edema",
            "percent": "0.8"
        },
        {
            "name": "Arthritis or arthralgia",
            "percent": "0.8"
        },
        {
            "name": "Abdominal pain",
            "percent": "0.8"
        },
        {
            "name": "Upper respiratory tract infections",
            "percent": "0.8"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "0.8"
        },
        {
            "name": "Potassium increased",
            "percent": "0.8"
        }
    ]
}